Investigating the Interplay between the Gut Microbiota and Host Immunity in Gastroenteric Disorders: The Potential of Combined Drug Therapies to Restore Microbial-immune Homeostasis.

Combination therapy demonstrated superior efficacy in enhancing gut microbial diversity compared to monotherapy and control groups.

• Retrospective, observational study of 100 patients with moderate to severe gastrointestinal disorders
• Conditions included irritable bowel syndrome and inflammatory bowel disease
• Three groups were compared: control, monotherapy, and combination therapy
• Study duration was 12 weeks
• Improvements were observed in alpha diversity metrics

Combination therapy was associated with a decrease in inflammatory indices in patients with gastroenteric disorders.

• Inflammatory indices were measured across control, monotherapy, and combination therapy groups
• The combination therapy group showed greater reductions in inflammatory markers compared to other groups
• The study involved 100 patients over a 12-week observation period

Combination therapy produced a shift in immune phenotype in patients with gastrointestinal disorders.

• Immune phenotype changes were observed alongside microbial diversity improvements
• The combination therapy group had better immune responses compared with the monotherapy and control groups
• Changes in immune phenotype were part of the broader microbial-immune homeostasis restoration

Patients receiving combination therapy experienced significant improvements in symptom severity, pain, and general health.

• Outcomes measured included symptom severity, pain, and general health
• The combination therapy group had better responses compared with the other groups
• Improvements were observed across the 12-week treatment period in 100 patients

Regression analysis revealed that microbial diversity, immune system regulation, and inflammation had positive effects on disease symptom alleviation.

• Regression analysis was used to identify factors contributing to symptom improvement
• Three key factors identified: microbial diversity, immune system regulation, and inflammation
• These factors were found to have positive effects on disease symptom alleviation
• Findings support combination therapy as a more comprehensive treatment approach for gastroenteric diseases